ACTO acquires CoHealth to open new frontier in patient education

ACTO, the Omnichannel Education and Engagement platform for life sciences, today announced its acquisition of CoHealth, a mobile application that provides trusted resources for patients and caregivers. The deal is ACTO’s second strategic acquisition since securing $11.5 million this summer, and brings a new division with direct-to-patient education capabilities to ACTO’s SaaS platform.

Lo Family Social Venture Fund gives 14 startups a boost

Eco-friendly textiles. 3D-printed smart soil. Portable, rapid testing for COVID-19. These are just three of the 14 promising, solutions-based social venture projects that received funding from the new Lo Family Social Venture Fund this fall. The fund, established earlier this year, helps U of T students and recent graduates take their social enterprises to the next level, providing support for student-driven ventures that will positively impact the global community.

Microchip acquires high-level synthesis tool provider LegUp to simplify development of PolarFire® FPGA-based Edge Compute Solutions

Microchip Technology Inc. (Nasdaq: MCHP) today announced it acquired Toronto-based LegUp Computing Inc., expanding its Field-Programmable Gate Array (FPGA)-based edge compute solution stack with a high-level synthesis (HLS) tool. Commercialized from University of Toronto research, the LegUp HLS tool will make it easier for a larger community of software engineers to harness the algorithm-accelerating power of Microchip’s PolarFire FPGA and PolarFire System on Chip (SoC) platforms.

A successful exit for U of T startup, LegUp Computing, acquired by Microchip

Microchip Technology Inc. (Nasdaq: MCHP) today announced it acquired Toronto-based LegUp Computing Inc., expanding its Field-Programmable Gate Array (FPGA)-based edge compute solution stack with a high-level synthesis (HLS) tool. Commercialized from University of Toronto research, the LegUp HLS tool will make it easier for a larger community of software engineers to harness the algorithm-accelerating power of Microchip’s PolarFire® FPGA and PolarFire System on Chip (SoC) platforms.

AmacaThera to commence Phase 1 clinical trial for non-opioid, post-operative pain management

AmacaThera Inc. is pleased to announce approval from Health Canada to proceed to a Phase 1 clinical trial with its lead asset, a long-acting anesthetic formulation for the treatment of post-surgical pain.

“This huge milestone was achievable due to all of the hard work and the relentless nature of the AmacaThera team,” co-founder and CEO Dr. Mike Cooke remarked.

Phenomic AI launches with $6 million financing and an AI/ML platform for targeting the tumor stroma

Phenomic AI, a biotech using AI/ML to reveal drug targets that emerge from cell-cell interactions and drive novel antibody drug discovery for challenging diseases, today announced the official launch of the company with US$6 million seed financing. The financing was led by CTI Life Sciences Fund and joined by AV8 Ventures, Luminous Ventures, and Viva BioInnovator.